InMode Ltd. (INMD) earns a Roarable Rating of B (Buy) with 74/100 RQD Confidence. High-quality cash engine (79% profit margin, 18% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
Altman Z-Score 9.20 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 4/9
FRED Regime × Technicals: 20% of 52W Range • RSI-14 at 24.2 (OVERSOLD (<32))
Put hedging (50% put share) caps near-term gamma upside (-8 pts vs max)
Even with a 74/100 (B) score, INMD faces multiple-compression risk if current valuation multiples re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.
Broader market pullbacks can still drag down strong stocks in the short run.
Dilution & Margin Drag: Cannibal Buyback (-2.08% YoY Shares) — any gross margin slip below 76.0% triggers an automatic RQD downgrade.
Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($14.38) or 200D SMA ($14.33) invalidates the momentum regime and cuts Target Base ($14.48) toward Bear Floor ($11.08).
InMode Ltd. (INMD) advanced +1.05% to $13.51, trading at 20% of its 52-week range ($12.72 – $16.67). High-quality cash engine (79% profit margin, 18% return on capital) with steady institutional support.
NEW YORK, October 19, 2026--Steel Partners Holdings L.P. (together with its affiliates, "Steel"), a significant, long-standing shareholder of InMode Ltd. ("InMode" or the "Company") (Nasdaq: INMD), today issued an open l
To All InMode Stakeholders:Steel Partners Holdings L.P. (together with its affiliates, "Steel") is a significant, long-standing shareholder of InMode Ltd. On July 9, 2026, we proposed to acquire up to 100% of
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -6.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on INMD today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for INMD. Explore sector supply chains on /butterfly.
Across 1016 tracked Health Care securities in the Roarable RQD universe, InMode Ltd. (INMD) ranks #57 by composite RQD confidence (74/100, grade B) and #390 by equity capitalization ($776.6M). Within this direct 5-issuer industry benchmark cohort, TMDX leads on earnings valuation at 12.2x trailing P/E, while TMDX leads on capital efficiency and profitability with 18.1% ROIC and 59.9% gross margin. INMD currently leads its immediate peer cohort in composite quantitative strength at 74/100 (B).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| INMD
ACTIVE
InMode Ltd. | B | 74/100 | — | 78.5% | 17.7% | +1.05% | $776.6M | Benchmark Subject |
| CBLL CeriBell Inc. | D | 45/100 | — | 87.9% | -35.0% | +2.20% | $1.07B | /cbll-vs-inmd → |
| CNMD CONMED Corporation | C | 62/100 | 28.9x | 54.6% | 7.8% | -0.09% | $1.36B | /cnmd-vs-inmd → |
| CV CapsoVision Inc. | D | 44/100 | — | 52.9% | -35.0% | -1.70% | $369.2M | /cv-vs-inmd → |
| TMDX TransMedics Group Inc. | C+ | 69/100 | 12.2x | 59.9% | 18.1% | +0.33% | $2.33B | /tmdx-vs-inmd → |
In its most recent audited fiscal period (FY2025, filed 2025-12-31), InMode Ltd. (INMD) reported GAAP revenue of $370.5M (-6.2% vs. FY2024 revenue of $394.8M , and -24.7% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of $85.3M, and free cash flow of $84.3M (-36.1% YoY). On the balance sheet, INMD closed FY2025 with $766.4M in total assets against $0 in total debt (Altman Z-Score: 9.20, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $370.5M | $0 | $85.3M | $84.3M | $766.4M | — |
| FY2024 (FY) | 2024-12-31 | $394.8M | $0 | $132.7M | $132.0M | $785.7M | — |
| FY2023 (FY) | 2023-12-31 | $492.0M | $197.9M | $176.8M | $176.8M | — | — |
As of 2026-11-01, InMode Ltd. (NASDAQ: INMD) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 74/100 at a spot price of $13.51 (+1.05% 1D, market cap $776.6M). Pillar breakdown: Fundamental Cash Engine 15/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 16/20, and SEC Balance-Sheet Forensics 15/20. Across 1016 tracked Health Care issuers, INMD ranks #57 in composite RQD confidence.
Within the Health Care sector (Biotechnology: Electromedical & Electrotherapeutic Apparatus), INMD carries a Roarable B (74/100 RQD), trailing P/E of N/A, gross margin of 78.5%, and ROIC of 17.7%. By comparison, CBLL (CeriBell Inc.) holds a D grade (45/100 RQD, P/E N/A, ROIC -35.0%, cap $1.07B) and CNMD (CONMED Corporation) posts a C grade (62/100 RQD, P/E 28.9x, ROIC 7.8%, cap $1.36B). Among the 5-stock peer group, TMDX leads on earnings multiple (12.2x) while TMDX leads on capital efficiency (18.1% ROIC).
Per INMD's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001742692), InMode Ltd. generated $370.5M in revenue (-6.2% YoY), $0 in net income, and $84.3M in free cash flow against $766.4M in total assets and $0 in total debt. Key quantitative strengths: Strong cash generator (79% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.
INMD last traded at $13.51 (+1.05% on volume of 370,624 shares), positioning the stock -6.05% below its 50-day simple moving average ($14.38) and -5.72% below its 200-day simple moving average ($14.33). Across its 52-week range of $12.72 to $16.67, INMD sits at the 20.0% percentile with a 14-day RSI of 24.2 (OVERSOLD (<32)) and an implied next-earnings move of ±3.2% ($13.08 to $13.94).
Why INMD Stock advanced +1.05% Today — RQD Quant Desk Flash. High-quality cash engine (79% profit margin, 18% return on capital) with steady institutional support.